- Policy
- KDCA “All hands on deck to seek COVID-19 vaccine"
- by Kim, Jung-Ju Sep 16, 2020 06:25am
- The first director of Korea Disease Control and Prevention Agency (KDCA) Jeong Eun-kyeong stated the government agency would provide all possible support for seeking vaccine and treatment to completely overcome the COVID-19 crisis. Also, she added the rare disease designation and R&D for disease testing and treatment would be expanded as
- Company
- Boryung,launches Tuvero (Arahkor Pre) in Mexico
- by An, Kyung-Jin Sep 16, 2020 06:25am
- Boryung announced on the 14th that it held a web symposium of Tuvero, a combination drug for hypertension and dyslipidemia, based on Kanarb in Mexico on the 11th (time in Korea) and began to launch in earnest. Tuvero is a combination drug that includes Kanarb(Fimasartan), an ARB (angiotensin II receptor blocker)-based hypertension drug
- Company
- ST Pharm, registered a global phase I of STP1002
- by An, Kyung-Jin Sep 16, 2020 06:25am
- A US clinical trial of a new oral colon cancer treatment drug being developed by ST Pharm is on track. One out of three local clinical trial institutions that announced their entry this year began recruiting subjects, taking the first step toward commercialization. According to clinicaltrials.gov operated by the National Institutes of Heal
- Company
- Giotrif competitor Vizimpro close to receiving reimbursement
- by Eo, Yun-Ho Sep 15, 2020 06:27am
- Sources report, Pfizer Korea is speeding up the procedure to introduce epidermal growth factor receptor (EGRF) tyrosine kinase inhibitors (TKI) into the market. According to the industry sources, a fifth EPGF TKI Vizimpro (dacomitini) has passed the Health Insurance Assessment and Review Service (HIRA) Cancer Deliberation Committee in la
- Policy
- Crovalimab by Roche is conducting phase III in Korea
- by Lee, Tak-Sun Sep 15, 2020 06:27am
- Soliris (Eculizumab), which has recorded high sales as a treatment for paroxysmal nocturnal hemoglobinuria (PNH), a rare disease, is undergoing phase III clinical trial in Korea. It is Crovalimab, excavated by Chugai in Japan and developed by Roche. On the 11th, the MFDS approved a phase III IND for 'RO7112689' submitted by IQVIA Korea. RO
- Policy
- Famvir licensed by Ildong is now manufactured locally
- by Lee, Tak-Sun Sep 15, 2020 06:26am
- Ildong Pharmaceutical is anticipating Famvir profit to improve as the drug licensed out by Novartis would be manufactured in South Korea. A shingles treatment Famvir is an original famciclovir drug that Novartis received approval to market in South Korea in year 2002. In 2018, Ildong Pharmaceutical acquired the sales rights over Famv
- Company
- The sales of antiemetic drug Nasea plummeted
- by Kim, Jin-Gu Sep 15, 2020 06:26am
- Sales in the domestic market declined after three types of domestic copyright rights, including the antiemetic drug Nasea (Ramosetron), were transferred from Astellas to Daiichi Sankyo, a Japanese pharmaceutical company. According to IQVIA, a drug research institute, Nasea's sales in the first half of this year were &8361;12.7 billion, d
- Policy
- New osteoporosis drug Evenity passed deliberation
- by Lee, Hye-Kyung Sep 15, 2020 06:26am
- Amgen Korea's bone formation promoting and bone resorption inhibitor Evenity PFS (Romosozumab) passed the deliberation. On the 11th, the HIRA (President, Sun Min Kim) released the results of the deliberation on the adequacy of medical benefits for the drugs applied for decision deliberated by the '9th Pharmaceutical Benefits Advisory Comm
- Company
- Listed pharma companies financially sound despite COVID-19
- by Kim, Jin-Gu Sep 14, 2020 06:16am
- Apparently, major South Korean pharmaceutical and bio companies have been maintaining the level of financial soundness from late last year for the first half of this year. One of their financial soundness indicators, net liabilities, showed similar level as late last year, which the experts analyze the industry is performing relatively well,
- Policy
- Fluarix Tetra, full-scale competition for flu vaccines
- by Lee, Tak-Sun Sep 14, 2020 06:15am
- The quadrivalent flu vaccine 'Fluarix Tetra', which was first introduced in Korea in 2015, was approved by the Ministry of Food and Drug Safety, and began to compete in the market in earnest. GSK's Fluarix Tetra is a representative imported vaccine that has been ranked at the top since its launch in 2015. However, it is expected to act as
